Takeda Takeda

Dr. Takeda Takeda


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2024 in British Journal of Surgery
Verified
Journal Article
Open access
PDF file
MGMyrte Gorris
Myrte Gorris
EBEduard A van Bodegraven
Eduard A van Bodegraven
MHMohammad Abu Hilal
Mohammad Abu Hilal
LBLouisa Bolm
Louisa Bolm
OBOlivier Busch
Olivier Busch
MBMarc G. Besselink
Marc G. Besselink
International guidelines on intraductal papillary mucinous neoplasm (IPMN) recommend a formal oncological resection including splenectomy when distal pancreatectomy is indicated. This study aimed to compare oncological and surgical outcomes after distal pancreatectomy with or without splenectomy in patients with presumed IPMN. An international, retrospective cohort study was undertaken in 14 high-volume centres from 7 countries including consecutive patients after distal pancreatectomy for IPMN (2005–2019). Patients were divided into spleen-preserving distal pancreatectomy (SPDP) and distal pancreatectomy with splenectomy (DPS). The primary outcome was lymph node metastasis (LNM). Secondary outcomes were overall survival, duration of operation, blood loss, and secondary splenectomy. Overall, 700 patients were included after distal pancreatectomy for IPMN; 123 underwent SPDP (17.6%) and 577 DPS (82.4%). The rate of malignancy was 29.6% (137 patients) and the overall rate of LNM 6.7% (47 patients). Patients with preoperative suspicion of malignancy had a LNM rate of 17.2% (23 of 134) versus 4.3% (23 of 539) among patients without suspected malignancy (P < 0.001). Overall, SPDP was associated with a shorter operating time (median 180 versus 226 min; P = 0.001), less blood loss (100 versus 336 ml; P = 0.001), and shorter hospital stay (5 versus 8 days; P < 0.001). No significant difference in overall survival was observed between SPDP and DPS for IPMN after correction for prognostic factors (HR 0.50, 95% c.i. 0.22 to 1.18; P = 0.504). This international cohort study found LNM in 6.7% of patients undergoing distal pancreatectomy for IPMN. In patients without preoperative suspicion of malignancy, SPDP seemed oncologically safe and was associated with improved short-term outcomes compared with DPS.

14 October 2020 in Journal of Hepato-Biliary-Pancreatic Sciences
Verified
Journal Article
Closed access
PDF file
TTTakeda Takeda
Takeda Takeda
ASAkio Saiura
Akio Saiura
YTYu Takahashi
Yu Takahashi
YIYosuke Inoue
Yosuke Inoue
YMYoshihiro Mise
Yoshihiro Mise
HIHiromichi Ito
Hiromichi Ito

20 February 2022 in Surgery
Verified
Journal Article
Closed access
TTTakeda Takeda
Takeda Takeda
HIHiroshi Imamura
Hiroshi Imamura
JYJiro Yoshimoto
Jiro Yoshimoto
YFYuki Fukumura
Yuki Fukumura
RYRyuji Yoshioka
Ryuji Yoshioka
ASAkio Saiura
Akio Saiura

12 June 2022 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
TTTakeda Takeda
Takeda Takeda
YMYoshihiro Mise
Yoshihiro Mise
HIHiromichi Ito
Hiromichi Ito
YOYoshihiro Ono
Yoshihiro Ono
TSTakafumi Sato
Takafumi Sato
ASAkio Saiura
Akio Saiura

24 August 2024 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
YNYasuhiro Nakamura
Yasuhiro Nakamura
TYTakehiro Yasukawa
Takehiro Yasukawa
YFYuki Fukumura
Yuki Fukumura
TTTakeda Takeda
Takeda Takeda
HIHiroshi Imamura
Hiroshi Imamura
AOAkira Orimo
Akira Orimo
Background: Pancreatic ductal adenocarcinoma (PDAC) has poor prognosis due to its low surgical eligibility and resistance to chemotherapy. Abundant stroma is characteristic of PDAC, and cancer-associated fibroblasts (CAFs) are a major stromal constituent, contributing to chemoresistance. Because neoadjuvant chemotherapy (NAC) is included in PDAC treatment as a standard regimen, the role of CAFs in NAC resistance must be studied. Although type IV collagen (COLIV) is present in the tumor of PDAC, the association between COLIV and disease advancement of NAC-treated PDAC is unclear. Methods: Using a cohort of NAC-treated patients with PDAC, we examined clinicopathological data and conducted immunohistochemical analysis of COLIV in tissue specimens prepared from surgically resected pancreas. Results and Conclusions: Our analysis revealed that ~50% of the cases were positive for COLIV in the stroma and diffuse COLIV staining was an independent poor prognosis factor alongside high serum CA19-9 before NAC treatment (>37 U/mL) and postsurgical residual tumors. Based on these findings, we propose that stromal COLIV staining can be used to predict prognosis in NAC-treated patients with PDAC after surgery. Additionally, these findings suggest a possibility that stromal COLIV staining indicates resistance to anticancer drugs and/or contributes to malignancy in PDAC.

2 October 2024 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
ATAtsushi Takahashi
Atsushi Takahashi
RYRyuji Yoshioka
Ryuji Yoshioka
SKShuichi Koike
Shuichi Koike
MFMasahiro Fujisawa
Masahiro Fujisawa
MOMasaru Oba
Masaru Oba
ASAkio Saiura
Akio Saiura